ERBB2 and breast carcinoma: To date, only the Supervised Trial of Aerobic versus Resistance Training (START) in breast cancer patients has published results, suggesting a protective exercise effect in patients diagnosed as human epidermal growth factor receptor 2 (HER2)-positive and patients who completed >85% of the average relative dose intensity of their originally planned chemotherapy regimen.